Concepedia

Shirley Ong

SO

Statistics

Publications

9

Citations

1.5K

H-Index

9

Active since

2014

Affiliations

The Ohio State University Wexner Medical Center(Current)

University of Arkansas for Medical Sciences

Memorial Sloan Kettering Cancer Center

Huntsman Cancer Institute

Texas Oncology

Shirley Ong is an author at The Ohio State University Wexner Medical Center specializing in medicine, oncology, and glioblastoma.

Publications per year

2014–2023

9

Publications

9

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

, , +13

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri, Vikas Patil, Leeor Yefet et al. · Nature Medicine · 2023 · 270 citations · Full text

, , +17

ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

Gelareh Zadeh, Frederick F. Lang, Mariza Daras et al. · Neuro-Oncology · 2018 · 33 citations · Full text

, , +16

LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

Gelareh Zadeh, Mariza Daras, Timothy F. Cloughesy et al. · Neuro-Oncology · 2020 · 26 citations · Full text

, , +17

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.

Andrew E. Sloan, Robin Buerki, Christopher Murphy et al. · Journal of Clinical Oncology · 2021 · 15 citations

, , +16

1–5 of 9